During the last few years several factors have contributed to an increasing change in the medical treatment of advanced colorectal cancer. Among them are the more general acceptance of the impact of chemotherapy on quality of life and survival in first as well as in second-line treatment, the introduction of new drugs and the definition of novel endpoints which can roughly be defined as “patient benefit”. For this reason the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group (GITCCG) felt it was appropriate to organize a workshop with experts from different countries and national groups to discuss in depth several aspects concerning the treatment of patients with advanced colorectal cancer.
AaronsonN.K., AhmedzaiS., BergmanB.: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology.J. Natl. Cancer Inst.,85: 365–376, 1993.
2.
Advanced Colorectal Cancer Meta-Analysis Project:Modulation of fluorouracil by folinic acid in patients with advanced colorectal cancer: evidence in terms of response rate.J. Clin. Oncol.,10: 896–903, 1992.
3.
Allen-MershT.G., EarlamS., FordyC.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.Lancet,344: 1255–1260, 1994.
4.
American Society of Clinical Oncology:Outcome of cancer treatment for technology assessment and cancer treatment guidelines.J. Clin. Oncol.,14: 671–679, 1996.
5.
AndersenJ.S., BurrisH.A., CasperE.: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer.Proc. Am. Soc. Clin. Oncol.,13: 461 (Abstr 1600), 1994.
6.
AndersonJ.R., CainK.C., GelberR.D.: Analysis of survival by tumor response.J. Clin. Oncol.,1: 710–719, 1983.
7.
ArandaE., CervantesA., AntonA.: A phase III multicenter randomized study in advanced colorectal cancer: fluorouracil high dose continuous infusion weekly versus fluorouracil + leucovorin.Preliminary results. Proc. Am. Soc. Clin. Oncol.,16: 281A, 1997.
8.
BécouarnY., YchouM., DucreuxM.: Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report.Proc. Am. Soc. Clin. Oncol.,16: 229A, 1997.
9.
BerettaG., BollinaR., CozziC.: Should we consider the weekly (w) chemotherapy (CT) with fluorouracil (F) + racemin folinic acid (f) a standard treatment for advanced/metastatic carcinoma of the digestive tract (DTC) in elderly patients (pts)?Proc. Am. Soc. Clin. Oncol., 16, 259a(abstr), 1997.
10.
BleibergH.: Colorectal cancer. Is there an alternative to 5-FU? Eur.J. Cancer,33: 536–541, 1997.
11.
BlijhamG., WagenerT., WilsJ.: Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer. Final results of a randomized European Organisation for Research and Treatment of Cancer study.J. Clin. Oncol.,14: 2266–2273, 1996.
12.
BrienzaS., VignoudJ., ItzhakiM., KrikorianA.: Oxaliplatin (L-OHP): global safety in 682 patients (pts).Proc. Am. Soc. Clin. Oncol.,14: 209 (Abstr), 1995.
13.
BurrisH.A., MooreM.J., AndersenJ.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J. Clin. Oncol.,15, 2403–2413, 1997.
14.
ButerJ., SinnigeH.A., CatsA.: Maintenance of remission on 5-fluorouracil (5-FU), leucovorin (LV) and alpha-2A interferon (IFN alpha) in advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol.,13: (abstr 557), 1994.
15.
BuyseM., PiedboisP.: On the relationship between response to treatment and survival time.Stats. Med.,15: 2797–2812, 1996.
16.
CaudryM., BonnelC., FloquetA.: A randomized study of bolus fluorouracil plus folinic acid versus 21 day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.Am. J. Clin. Oncol.,18: 118–125, 1995.
17.
CellaD.F., TulskyD.S., GrayG.: The functional assessment of cancer therapy scale: development and validation of the general measure.J. Clin. Oncol.,11: 570–579, 1993.
18.
CellaD.F., TulskyD.S.: Measuring quality of life today: methodological aspects.Oncology,4: 29–38, 1990.
19.
ChuD.Z., RiksonC.A., RussellM.P.: Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence.Arch. Surg.,126: 314–316, 1991.
20.
Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.J.Clin. Oncol.,14: 2843–2877, 1996.
21.
CunninghamD., ZalcbergJ., RathU.: Final results of a randomised trial comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer.Ann. Oncol.,7: 961–965, 1996.
22.
CunninghamD., ZalcbergJ.R., RathU.: Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The Tomudex Colorectal Cancer Study Group.Eur. J. Cancer, 31A: 1945–1954, 1995.
23.
De GramontA., BossetJ.F., MilanC.: Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusions for advanced colorectal cancer. A French Intergroup Study.J. Clin. Oncol.,15: 808–815, 1997.
24.
de GramontA., VignoudJ., TournigandC.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.Eur. J. Cancer,33: 214–219, 1997.
25.
De HaesJ.C.J.M., van KnippenbergF.C.E., NeijtJ.P.: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Check-List.Br. J. Cancer,62: 1034–1038, 1990.
26.
FagesB., CoteC., GruiaG.: Tumor response and stabilization rates are worthwhile surrogate efficacy endpoints in metastatic colorectal cancer. Analysis of data in 455 5-FU resistant patients treated with CPT11 (in preparation).
27.
FallowfieldL.: Quality of quality of life data.Lancet,348: 421, 1996.
28.
FieldingL.P., PettigrewN.: College of American Pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors.Arch. Pathol. Lab. Med.,119: 1115–1121, 1995.
29.
FindlayM., Van CutsemE., KochaW.: A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer.Am. Soc. Clin. Oncol.,16: 227A, 1997.
30.
GiacchettiS., ZidaniR., PerpointB.: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC).Proc. Am. Soc. Clin. Oncol.,16: 229A, 1997.
31.
GlimeliusB., HoffmanK., GrafW.: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer.Cancer,73: 556–562, 1994.
32.
GlimeliusB., HoffmanK., OlafdottirM.: Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens.Eur. J. Cancer Clin. Oncol.,25: 829–835, 1989.
33.
GrafW., PahlmanL., BergstromR., GlimeliusB.: The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.Br. J. Cancer,70: 559–563, 1994.
34.
GrillR., OxmanA.D., JulianJ.A.: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J.Clin. Oncol.,11: 1866–1872, 1993.
35.
HejnaM., KornekG., WeinlnderG.: Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.Acta Chir. Austr., Suppl115: 52, 1995.
36.
HowellA., MackintoshJ., JonesM.: The definition of the “No Change” category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.Eur. J. Cancer Clin. Oncol.,24: 1557–1572, 1996.
37.
JägerE., HeikeM., BernhardH.: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial.J. Clin. Oncol.,14: 2274–2279, 1996.
38.
JohnsonJ.R., TempleR.: Food and Drug Administration requirements for approval of new anticancer drugs.Cancer Treat. Rep.,69: 1155–1159, 1985.
39.
KöhneC., SchöffskiP., WilkeH.: Biochemical modulation of weekly high-dose infusional (HD-CI) 5-FU in patients with advanced colorectal cancer. Results of a multicenter randomized AIO trial.Proc. Am. Soc. Clin. Oncol.,16: 271A, 1997.
40.
KöhneC.H., HeckerH., SchöffskiP.: Weekly high dose infusional (CI) 5-FU plus folinic acid (FA) has major impact on survival in patients with advanced colorectal cancer. Results of a multivariate analysis using RECPAM.Proc. Am. Soc. Clin. Oncol.,15: 201A, 1996.
41.
KöhneC.H., HiddemannW., SchüllerJ.: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.J. Clin. Oncol.,13: 1201–1208, 1995.
42.
Köhne-WömpnerC.H., SchmollH.F., HarstrickA., RustumY.M.: Chemotherapeutic strategies in metastatic colorectal cancer. An overview of current clinical trials.Semin. Oncol.,19: 105–125, 1992.
43.
LabiancaR., CascinuS., FrontiniL.: High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study.Ann. Oncol.,8: 169–174, 1997.
44.
LabiancaR., PanceraG., AitiniE.: Folinic acid + 5-Fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer).Ann. Oncol.,2: 673–679, 1991.
45.
LeichmanC.G., FlemingT.R., MuggiaF.M.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study.J. Clin. Oncol.,13: 1303–1311, 1995.
46.
LéviF.A., ZidaniR., VannetzelJ.-M.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folonic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.J. Natl. Cancer Inst.,86: 1608–1617, 1994.
47.
LokichJ.J., AhlgrenJ.D., GulloJ.J.: A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus administration schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.J. Clin. Oncol., 1989, 7: 425–432.
48.
MachoverD., Diaz-RubioE., de GramontA.: Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.Ann. Oncol.,7: 95–98, 1996.
49.
MeyerowitzB.E.: Quality of life in breast cancer patients. The contribution of data to the care of patients.Eur. J. Cancer.,29A: S 59–62, 1993.
50.
MoertelC.G., FlemingT.R., MacdonaldJ.S.: Fluorouracil plus levamisol as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.Ann. Intern. Med.,122: 321–326, 1995.
51.
Nordic Gastrointestinal tumor Adjuvant Therapy Group:Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.J. Clin. Oncol.,10: 904–911, 1992.
52.
O'LearyJ.F., FaircloughD.L., JankowskiM.K.: Comparison of time trade off utilities and rating scale values in cancer patients and their relatives.J. Med. Decis. Making,15: 132–137, 1995.
53.
PazdurR., LassereY., RhodesV.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.J. Clin. Oncol.,12: 2296–2300, 1994.
54.
PitotH.C., WenderD.B., O'ConnellM.J.: Phase II trial of irinotecan in patients with metastatic colorectal cancer.J. Clin. Oncol.,15: 2910–2919, 1997.
55.
RevickiD.A.: Assessing health related quality of life in clinical trials and practice settings: an overview, pp. 350–355, AS-CO Educational Book, 1997.
56.
RossP., NormanA., CunninghamD.: A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol.,16: 271A, 1997.
57.
RothenbergM.L., MooreM.J., CrippsM.C.: A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer.Ann. Oncol.,7, 347–353, 1996.
58.
RougierP., BugatR., DouillardJ.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil based chemotherapy.J. Clin. Oncol.,15: 251–260, 1997.
59.
RougierP., BugatR., MartyM.: Efficacy of CPT-11 in CRC patients progressive on 5-FU-based chemotherapy, p. 97 In: VIth EORTC GITCCG Symposium: an update after 25 years of experience, Nijmegen 1996.
60.
RougierPh., PaillotB., LaplancheA.: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer.Eur. J. Cancer,33: 1789–1793, 1997.
61.
SahmoudT., GrabowskaE., BlijhamG.: The identification of high risk patients with metastatic colorectal cancer. Abstr. 9th European Cancer Conference (ECCO 9), Hamburg, September 14-18, 1997.
62.
ScheithauerW., DepischD., KornekG.: Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer.Cancer,73: 1562–1568, 1994.
63.
ScheithauerW., KornekG., MarczellA.: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III.J. Clin. Oncol.,15: 908–914, 1997.
64.
ScheithauerW., RosenH., KornekG.V.: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.Br. Med. J.,306: 752–755, 1993.
65.
SchipperH., ClinchJ., McMurrayA., LevittM.: Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation.J. Clin. Oncology,2: 472–483, 1984.
66.
SchmollH.J.: Is there a second line chemotherapy in colorectal cancer? Educational book of the 21st ESMO Congress, Vienna, Austria, November 1-5, 1996, pp. 35–42.
67.
SchöffskiP., SchellenbergerU., KöhneC.H.: Quality of life predicts for both response and survival in patients treated for metastatic colorectal cancer. Results of a randomized phase II study.Proc. Am. Soc. Clin. Oncol.,15: 213, 1996.
68.
SchulmanK., JohnsonA., RathoreS.: The use of satisfaction measures in Oncology.ASCO Educational Book, pp. 337–341, 1997.
69.
SmythJ.F., HardcastleD., DentonG.: Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.Ann. Oncol.,6: 948–949, 1995.
70.
SobreroA., AscheleC., BertinoJ.: Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation.J. Clin. Oncol.,15: 368–381, 1997.
71.
SteinB.N., PetrelliN.J., DouglassH.O.: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.Cancer,75: 11–17, 1995.
72.
StoffregenC., ZurbornK.H., BoehmeV.: Weekly high-dose 5-fluorouracil 24-hours infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer.Oncologie,19: 410–441, 1996.
73.
TorranceG.W.: Measurement of health state utilities for economic appraisal.J. Health Econ.,5: 1–30, 1985.
74.
TsevatJ., WeeksJ.C., GuadagnoliE.: Using health related quality of life information; clinical encounters, clinical trials and health policies.J. Gen. Intern. Med.,9: 576–582, 1994.
75.
Van CutsemE., RougierPh., DrozJ.P.: Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU.Proc. Am. Soc. Clin. Oncol.,16: 268A, 1997.
76.
Van CutsemE.: A glimpse of the future. New directions in the treatment of colorectal cancer.Eur. J. Cancer, 32A (Suppl 5): S23–27, 1996.
77.
WebbA., Scott MackieP., CunninghamD.: The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.Ann. Oncol.,6: 581–587, 1995.
78.
WilsJ.A.: High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Sem.Oncol., 19,2(suppl. 3): 126–130, 1992.
79.
ZalcbergJ.R., CunninghamD., Van CutsemE.: Tomudex (ZD1694), a novel thymidylate synthase inhibitor, has substantial activity in the treatment of patients with advanced colorectal cancer.J. Clin. Oncol.,14: 716–721, 1996.
